Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?
Executive Summary
Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon
You may also be interested in...
NME Outlook: Diabetes Drugs May Be Head Of The Class In 2005
The coming year could bring three significant approvals for novel classes of diabetes drugs: Amylin's Symlin, Lilly/Amylin's exenatide and Bristol-Myers Squibb/Merck's muraglitazar
NME Outlook: Diabetes Drugs May Be Head Of The Class In 2005
The coming year could bring three significant approvals for novel classes of diabetes drugs: Amylin's Symlin, Lilly/Amylin's exenatide and Bristol-Myers Squibb/Merck's muraglitazar
Ivax Launches Neurontin Generic “At Risk” As Pregabalin User Fee Date Nears
Ivax' "at risk" launch of generic gabapentin comes less than two weeks before the anticipated FDA user fee date for Pfizer's Neurontin follow-on drug Lyrica